|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Key Words: dyspepsia Helicobacter pylori
| The first 150 words of the full text of this article appear below. |
Design
Randomised {allocation concealed*}
, blinded (clinicians, patients, data collectors, outcome assessors, {data analysts, and manuscript writers}
),* placebo controlled trial with 1 year of follow up.
Setting
36 family practices in Canada.
Patients
294 patients (mean age 49 y, 50% men) who were
18 years of age and had uninvestigated symptoms of dyspepsia for
3 months. Dyspepsia was defined as a complex of epigastric pain including heartburn, acid regurgitation, excessive burping or belching, increased abdominal bloating, nausea, abnormal or slow digestion, or early satiety. All patients had to have positive test results for H pylori on the Helisal rapid blood test and the 13C-urea breath test. Exclusion criteria included gastrooesophageal reflux disease, upper gastrointestinal investigation in the previous 6 months or
2 times in the past 10 years, eradication therapy for H pylori in the past 6 months, previous gastric surgery, ulcer disease or endoscopic oesophagitis, and irritable bowel syndrome. Follow
Brendan Delaney, MD, FRCP, MRCGP
University of Birmingham
Birmingham, UK
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |